These contradictory findings, which have added yet another layer of complexity to our understanding of the role of PXR in lipid metabolism homeostasis and NAFLD, may be explained by different genetic backgrounds of mice used and PCN treatment dosage and schedules. The gene discussed is NR1I2; the disease is metabolic dysfunction-associated steatotic liver disease.